Effect of silymarin in treatment of adverse effects of anti tuberculosis drugs.

Evaluation of Silymarin in treatment of anti tuberculosis drug induced hepatitis in patients newly diagnosed with tuberculosis.

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

ANZCTR

Registry ID

ACTRN12610000643077

Enrollment

Registered

2010-08-09

Start date

2010-10-01

Completion date

Unknown

Last updated

2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

Adverse effects of antituberculosis drugs are frequent, sometimes with morbidity and even may be fatal, most serious of them is drug induced hepatitis. As Sylimarin in rat model has been effective in prevention and treatment of hepatic adverse effects of anti tuberculosis drugs, we decide to investigate this study.

Interventions

Silymarin 420 mg per day,in three doses, It will start after diagnosis of drug induced hepatitis and stop after normalization of liver function tests, as oral tablets

Study design

Allocation

Randomised controlled trial

Primary purpose

Treatment

Masking

Blinded (masking used)

Eligibility

Sex/Gender

All

Age

18 Years to 100 Years

Healthy volunteers

Inclusion criteria

New cases of tuberculosis

Exclusion criteria

1. Infection with Human Immune deficiency virus 2. Infection with hepatitis B virus 3. Infection with hepatitis c virus 4.pregnancy 5. Breast feeding

Outcome results